BGNE:NGS-BeiGene Ltd. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 205.04

Change

-0.43 (-0.21)%

Market Cap

USD 1.04B

Volume

0.33M

Analyst Target

USD 237.90
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

BeiGene Ltd is a clinical-stage biopharmaceutical company engaged in the discovery & development of molecularly targeted & immuno-oncology drugs for the treatment of cancer. Its product include BGB-3111, BGB-283 and BGB-290 and one immuno-oncology agent.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-11 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-11.72 (-2.34%)

USD 121.60B
REGN Regeneron Pharmaceuticals Inc

-4.68 (-0.57%)

USD 92.70B
ALNY Alnylam Pharmaceuticals Inc

-10.87 (-3.88%)

USD 36.09B
ARGX argenx NV ADR

+5.01 (+0.85%)

USD 35.78B
MRNA Moderna Inc

+0.72 (+1.68%)

USD 21.00B
UTHR United Therapeutics Corporatio..

+0.43 (+0.11%)

USD 16.70B
RPRX Royalty Pharma Plc

-0.36 (-1.37%)

USD 16.11B
INCY Incyte Corporation

-0.95 (-1.17%)

USD 14.67B
SMMT Summit Therapeutics PLC

-1.01 (-4.64%)

USD 13.75B
PCVX Vaxcyte Inc

-4.26 (-4.11%)

USD 13.28B

ETFs Containing BGNE

XSNR:LSE Xtrackers - Stoxx Europe .. 8.01 % 0.00 %

-312.00 (-1.60%)

USD 0.03B
DXSL:XETRA Xtrackers - Stoxx Europe .. 8.01 % 0.00 %

-4.88 (-1.60%)

USD 0.02B
MSGR 6.80 % 0.00 %

N/A

N/A
L6EW:LSE Ossiam Stoxx Europe 600 E.. 6.12 % 0.00 %

-154.00 (-1.60%)

USD 0.12B
S6EW:PA Ossiam Stoxx Europe 600 E.. 6.12 % 0.00 %

-2.66 (-1.60%)

USD 0.12B
OSX6:XETRA Ossiam Stoxx Europe 600 E.. 6.12 % 0.00 %

-1.44 (-1.60%)

USD 0.16B
S6EW:SW Ossiam STOXX® Europe 600.. 6.12 % 0.00 %

N/A

USD 0.12B
ETLI:XETRA L&G Pharma Breakthrough U.. 3.16 % 0.00 %

-0.18 (-1.60%)

USD 0.02B
ELOVD:SW UBS(Lux)Fund Solutions .. 1.98 % 0.00 %

-0.23 (-1.60%)

N/A
ELOW:PA SSgA SPDR ETFs Europe II .. 1.31 % 0.00 %

N/A

USD 0.02B
ZPRL:F SPDR® EURO STOXX Low Vol.. 1.31 % 0.00 %

-0.89 (-1.60%)

USD 0.02B
ZPRL:XETRA SPDR® EURO STOXX Low Vol.. 1.31 % 0.00 %

-0.93 (-1.60%)

USD 0.02B
ELOW:SW SPDR® EURO STOXX Low Vol.. 1.17 % 0.00 %

-0.82 (-1.60%)

N/A
PHR:CA 0.00 % 0.78 %

N/A

N/A
KURE KraneShares MSCI All Chin.. 0.00 % 0.79 %

-0.10 (-1.60%)

USD 0.04B
EDGE:CA Evolve Innovation Index F.. 0.00 % 0.60 %

-0.20 (-1.60%)

CAD 0.04B
KMED 0.00 % 0.79 %

N/A

N/A
GDNA 0.00 % 0.00 %

N/A

N/A
XRE:CA iShares S&P/TSX Capped RE.. 0.00 % 0.61 %

-0.03 (-1.60%)

CAD 1.48B
FLHK Franklin FTSE Hong Kong E.. 0.00 % 0.09 %

-0.38 (-1.60%)

USD 0.01B
S6EW:LSE Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

-2.63 (-1.60%)

N/A
LOWE:LSE 0.00 % 0.00 %

N/A

N/A
XMLA:LSE Xtrackers MSCI EM Latin A.. 0.00 % 0.00 %

+29.50 (+-1.60%)

N/A
XMLD:LSE Xtrackers MSCI EM Latin A.. 0.00 % 0.00 %

+0.03 (+-1.60%)

N/A
XS3R:LSE Xtrackers MSCI Europe Con.. 0.00 % 0.00 %

-82.00 (-1.60%)

USD 0.06B
XDGM:LSE 0.00 % 0.00 %

N/A

N/A
EMMV:PA 0.00 % 0.00 %

N/A

N/A
DXSK:F Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

-1.94 (-1.60%)

N/A
EUN0:F iShares Edge MSCI Europe .. 0.00 % 0.00 %

-0.92 (-1.60%)

N/A
OSX6:F Ossiam Lux - Ossiam Stoxx.. 0.00 % 0.00 %

-2.40 (-1.60%)

N/A
DXSK:XETRA Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

-1.82 (-1.60%)

USD 0.07B
EUN0:XETRA iShares Edge MSCI Europe .. 0.00 % 0.00 %

-1.02 (-1.60%)

USD 0.79B
OSX9:XETRA 0.00 % 0.00 %

N/A

N/A
UIMY:XETRA 0.00 % 0.00 %

N/A

N/A
BIOT 0.00 % 0.00 %

N/A

N/A
EDGE-U:CA Evolve Innovation Index F.. 0.00 % 0.00 %

N/A

N/A
LCDE:XETRA BNP Paribas Easy - Low Ca.. 0.00 % 0.00 %

-0.22 (-1.60%)

USD 0.02B
MVEU:SW iShares Edge MSCI Europe .. 0.00 % 0.00 %

-0.93 (-1.60%)

USD 0.81B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.68% 68% D+ 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.68% 68% D+ 64% D
Trailing 12 Months  
Capital Gain 3.11% 50% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.11% 50% F 37% F
Trailing 5 Years  
Capital Gain 3.92% 71% C- 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.92% 71% C- 43% F
Average Annual (5 Year Horizon)  
Capital Gain 8.86% 57% F 60% D-
Dividend Return 8.86% 57% F 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.64% 63% D 37% F
Risk Adjusted Return 17.15% 70% C- 50% F
Market Capitalization 1.04B 99% N/A 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 6.45 23% 19%
Price / Cash Flow Ratio -19.74 88% 88%
Price/Free Cash Flow Ratio -11.91 93% 90%
Management Effectiveness  
Return on Equity -14.62% 91% 47%
Return on Invested Capital -27.04% 74% 30%
Return on Assets -9.69% 89% 35%
Debt to Equity Ratio 5.59% 62% 77%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.